Afatinib vs Dacomitinib PF-00299804
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR/HER1, HER2, HER4 · full Non-Small Cell Lung Cancer pipeline
Afatinib · Gilotrif
Marketed by Boehringer Ingelheim
NCT00949650 · Phase 3 · completed
The study randomly assigned 345 participants to afatinib or active chemotherapy, but it was open-label rather than blinded. Its hard clinical primary endpoint, centrally assessed progression-free survival, was statistically significantly better with afatinib, but the lack of blinding limits the strength of the evidence.
Next expected readout: December 2026 · NCT04413201 (registry estimate)
Reported efficacy
Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7) (met)
Result source: NCT01121393
Dacomitinib PF-00299804
Rights held by Pfizer; US product discontinued
NCT01774721 · Phase 3 · completed
The 452 participants were randomly assigned to dacomitinib or the active comparator gefitinib, but the study was open-label rather than double-blinded. The hard clinical primary endpoint, independently assessed progression-free survival, was met in favor of dacomitinib, but the lack of blinding limits the strength of the evidence.
Next expected readout: April 2027 · NCT04946968 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11) (met)
Result source: NCT01774721
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Afatinib | Dacomitinib PF-00299804 |
|---|---|---|
| PFS, median | 11.2 vs 6.9vs Pemetrexed/CisplatinNCT0094965022 other results
| 14.7 vs 9.2vs GefitinibNCT0177472111 other results
|
| OS, median | 28.2 vs 28.2vs Pemetrexed/CisplatinNCT0094965010 other results
| 6.8 vs 6.3+0.5 vs placeboNCT010000258 other results
|
| ORR | 67.8% vs 23%vs Gemcitabine / CisplatinNCT0112139314 other results
| 7.1% vs 1.3%+5.8 vs placeboNCT010000255 other results
|
| Duration of response, median | 9.7 vs 4.3vs Gemcitabine / CisplatinNCT011213936 other results
| 9.2 vs 10.1vs ErlotinibNCT013605548 other results
|
PFS, median
- Afatinib
- 11.2 vs 6.9vs Pemetrexed/CisplatinNCT00949650
22 other results
- 11.0 vs 5.6 NCT01121393
- 2.6 vs 1.9 NCT01523587
- 5.5 vs 2.9 NCT01085136
- 3.3 vs 1.1 NCT00656136
- 3.1 NCT01085136
- 15.4 NCT01814553
- 9.9 NCT01814553
- 10.9 NCT02208843
- 1.9 NCT00796549
- 10.2 NCT00525148
- 4.6 NCT01090011
- 2.8 NCT02597946
- 0.9 NCT01003899
- 3.7 NCT00730925
- 2.7 NCT01090011
- 2.9 NCT01090011
- 2.1 NCT03157089
- 3.3 NCT03157089
- 3.7 NCT02369484
- 5.9 NCT02364609
- 1.4 NCT02364609
- 4.2 NCT01090011
- Dacomitinib PF-00299804
- 14.7 vs 9.2vs GefitinibNCT01774721
11 other results
- 2.6 vs 2.5 NCT01360554
- 2.6 vs 2.5 NCT01360554
- 2.7 vs 1.6 NCT01000025
- 16.6 vs 11 NCT01774721
- 1.9 vs 1.9 NCT01360554
- 1.9 vs 1.9 NCT01360554
- 2.9 vs 1.9 NCT00769067
- 11.5 NCT00818441
- 2.3 NCT01858389
- 1.6 NCT01858389
- 2.6 NCT00818441
OS, median
- Afatinib
- 28.2 vs 28.2vs Pemetrexed/CisplatinNCT00949650
10 other results
- 23.1 vs 23.5 NCT01121393
- 7.8 vs 6.8 NCT01523587
- 12.3 vs 13.1 NCT01085136
- 18.4 NCT00711594
- 11.6 NCT00796549
- 26.8 NCT00525148
- 10.0 NCT02597946
- 8.8 NCT03157089
- 6.1 NCT03157089
- 12.9 NCT02369484
- Dacomitinib PF-00299804
- 6.8 vs 6.3+0.5 vs placeboNCT01000025
8 other results
- 7 vs 5.2 NCT01000025
- 7.2 vs 7.5 NCT01000025
- 34.1 vs 27 NCT01774721
- 7.9 vs 8.3 NCT01360554
- 8.1 vs 8.5 NCT01360554
- 9.6 vs 7.5 NCT00769067
- 29.5 NCT00818441
- 9.3 NCT00818441
ORR
- Afatinib
- 67.8% vs 23%vs Gemcitabine / CisplatinNCT01121393
14 other results
- 31.2% vs 13.2% NCT01085136
- 8.5% NCT01085136
- 50% NCT02208843
- 13% NCT00796549
- 62% NCT00525148
- 0% NCT02597946
- 0% NCT01003899
- 2% NCT00730925
- 16.7% NCT03157089
- 8.3% NCT03157089
- 13% NCT00796549
- 11.6% NCT00796549
- 17% NCT02364609
- 25% NCT02364609
- Dacomitinib PF-00299804
- 7.1% vs 1.3%+5.8 vs placeboNCT01000025
5 other results
- 74.9% vs 71.6% NCT01774721
- 75.3% vs 70.2% NCT01774721
- 6.3% NCT01858389
- 17% vs 5.3% NCT00769067
- 50.5% NCT04511533
Duration of response, median
- Afatinib
- 9.7 vs 4.3vs Gemcitabine / CisplatinNCT01121393
6 other results
- 10.5 NCT00796549
- 17.6 NCT00525148
- 9 NCT01090011
- 3.9 NCT01090011
- 5.8 NCT01090011
- 0 NCT01090011
- Dacomitinib PF-00299804
- 9.2 vs 10.1vs ErlotinibNCT01360554
8 other results
- 10.4 vs 9.2 NCT01360554
- 16.6 vs 9.3 NCT00769067
- 11.1 NCT04511533
- 12.9 NCT00818441
- 12.4 NCT00818441
- 2.8 NCT01858389
- 10.4 NCT00548093
- 2.8 NCT00548093
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. Afatinib: 11 of 11 rows · Dacomitinib PF-00299804: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Afatinib Rows use multiple source trials | Dacomitinib PF-00299804 Rows use multiple source trials |
|---|---|---|
| Disease Control responder rate · % of participants No placebo or comparator arm | 83.3% (n=60)40 mga,b,c,d NCT02208843 · Phase 4 · registry result, not featured evidence 6 other source trials58.3% (n=12)30 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination 50% (n=12)40 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination 61.1% (n=18)40 mg NCT02597946 · Phase 2 · registry result, not featured evidence 50.7% (n=69)50 mg NCT00796549 · Phase 2 · registry result, not featured evidence 59% (n=41)50 mg NCT00730925 · Phase 2 · registry result, not featured evidence 24% (n=38)40 mg NCT01003899 · Phase 2 · registry result, not featured evidence | 50% (n=16)45/60 mga,b,c,d NCT01858389 · Phase 2 · registry result, not featured evidence |
| Duration of Response time to event · months No placebo or comparator arm | 17.65 months*e,b,c,d NCT00525148 · Phase 2 · converted to months from 76.5 weeks as posted 5 other source trials10.5 months*50 mg NCT00796549 · Phase 2 · registry result, not featured evidence · converted to months from 45.5 weeks as posted 0 monthsAfa40+Ctx250 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 9 monthsAfa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 3.9 monthsAfa40 Mono NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy 5.8 monthsAfa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination | 11.1 monthse,b,c,d NCT04511533 · Phase 4 · registry result, not featured evidence 5 other source trials2.83 months45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence 12.9 months NCT00818441 · Phase 2 · registry result, not featured evidence 12.4 months NCT00818441 · Phase 2 · registry result, not featured evidence 10.43 months* NCT00548093 · Phase 2 · registry result, not featured evidence · converted to months from 45.2 weeks as posted 2.79 months* NCT00548093 · Phase 2 · registry result, not featured evidence · converted to months from 12.1 weeks as posted |
| ORR responder rate · % of participants No placebo or comparator arm | 62% (n=129)e,b,c,d NCT00525148 · Phase 2 11 other source trials50% (n=60)40 mg NCT02208843 · Phase 4 · registry result, not featured evidence 8.5% (n=1154) NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy 8.3% (n=12)30 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination 16.7% (n=12)40 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination 0% (n=18)40 mg NCT02597946 · Phase 2 · registry result, not featured evidence 13% (n=69)50 mg NCT00796549 · Phase 2 · registry result, not featured evidence 13% (n=69) @ 96wk50 mg NCT00796549 · Phase 2 · registry result, not featured evidence 2% (n=41)50 mg NCT00730925 · Phase 2 · registry result, not featured evidence 0% (n=38)40 mg NCT01003899 · Phase 2 · registry result, not featured evidence 17% (n=6) NCT02364609 · Phase 1 · registry result, not featured evidence · combination 25% (n=4) NCT02364609 · Phase 1 · registry result, not featured evidence · combination | 50.5% (n=101)e,b,c,d NCT04511533 · Phase 4 · registry result, not featured evidence 1 other source trial6.3% (n=16)45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence |
| Overall Survival time to event · months No placebo or comparator arm | 26.8 monthsb,c,d NCT00525148 · Phase 2 6 other source trials6.14 months*30 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 26.6 weeks as posted 8.75 months*40 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 37.9 weeks as posted 10.02 months40 mg NCT02597946 · Phase 2 · registry result, not featured evidence 12.92 months* NCT02369484 · Phase 2 · registry result, not featured evidence · converted to months from 56 weeks as posted 18.4 months50 mg NCT00711594 · Phase 2 · registry result, not featured evidence 11.64 months*50 mg NCT00796549 · Phase 2 · registry result, not featured evidence · converted to months from 50.43 weeks as posted | 29.5 monthsf,b,c,d NCT00818441 · Phase 2 · registry result, not featured evidence show 1 more dose9.3 months NCT00818441 · Phase 2 · registry result, not featured evidence |
| Partial responder rate · % of participants No placebo or comparator arm Partial Response | 58.3% (n=24)*g,b,c,d Partial Response NCT01074177 · Phase na · registry result, not featured evidence · converted to % from 14 participants as posted | 52.8% (n=89)*f,g,b,c,d NCT00818441 · Phase 2 · registry result, not featured evidence · converted to % from 47 participants as posted show 1 more dose10% (n=30)* NCT00818441 · Phase 2 · registry result, not featured evidence · converted to % from 3 participants as posted |
| PFS time to event · months No placebo or comparator arm | 10.2 monthsb,c,d NCT00525148 · Phase 2 17 other source trials10.94 months40 mg NCT02208843 · Phase 4 · registry result, not featured evidence 3.15 months NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy 15.4 months40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination 9.9 months40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination 3.32 months*30 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 14.4 weeks as posted 2.08 months*40 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 9 weeks as posted 2.76 months40 mg NCT02597946 · Phase 2 · registry result, not featured evidence 3.67 months* NCT02369484 · Phase 2 · registry result, not featured evidence · converted to months from 15.9 weeks as posted 1.95 months*50 mg NCT00796549 · Phase 2 · registry result, not featured evidence · converted to months from 8.43 weeks as posted 3.66 months*50 mg NCT00730925 · Phase 2 · registry result, not featured evidence · converted to months from 15.86 weeks as posted 0.94 months*40 mg NCT01003899 · Phase 2 · registry result, not featured evidence · converted to months from 4.07 weeks as posted 5.88 months* NCT02364609 · Phase 1 · registry result, not featured evidence · combination · converted to months from 179 days as posted 1.38 months* NCT02364609 · Phase 1 · registry result, not featured evidence · combination · converted to months from 42 days as posted 4.2 monthsAfa40+Ctx250 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 4.6 monthsAfa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 2.7 monthsAfa40 Mono NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy 2.9 monthsAfa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination | 2.3 months45/60 mgf,b,c,d NCT01858389 · Phase 2 · registry result, not featured evidence show 1 more dose1.6 months45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence |
| Stable Disease event count · % of participants No placebo or comparator arm Stable disease | 46.2% (n=13)*b,c,d Stable disease NCT02369484 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted | 30.3% (n=89)*f,b,c,d NCT00818441 · Phase 2 · registry result, not featured evidence · converted to % from 27 participants as posted show 1 more dose36.7% (n=30)* NCT00818441 · Phase 2 · registry result, not featured evidence · converted to % from 11 participants as posted |
| Dropout rate | n/a: no completion milestone40 mgh NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 32 more results—50 mg/Day NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone50 mg/Day NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —40 mg NCT00525148 · Phase 2 —50 mg NCT00525148 · Phase 2 100%40mg NCT01121393 · Phase 3 n/a: no completion milestone NCT01523587 · Phase 3 n/a: no completion milestone40 mg NCT02208843 · Phase 4 · registry result, not featured evidence n/a: no completion milestone NCT01853826 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT01953913 · Phase 3 · registry result, not featured evidence 0%40 mg NCT02044380 · Phase 3 · registry result, not featured evidence 28%Afatinib Monotherapy (Part A) NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy —Afatinib Plus Paclitaxel (Part B) NCT01085136 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone40 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone30 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone40 mg NCT02597946 · Phase 2 · registry result, not featured evidence 0% NCT02369484 · Phase 2 · registry result, not featured evidence n/a: no completion milestone40 mg NCT00711594 · Phase 2 · registry result, not featured evidence n/a: no completion milestone50 mg NCT00711594 · Phase 2 · registry result, not featured evidence n/a: no completion milestone50 mg NCT00711594 · Phase 2 · registry result, not featured evidence n/a: no completion milestone20 mg NCT00711594 · Phase 2 · registry result, not featured evidence n/a: no completion milestone50 mg NCT00796549 · Phase 2 · registry result, not featured evidence n/a: no completion milestone50 mg NCT00730925 · Phase 2 · registry result, not featured evidence n/a: no completion milestone40 mg NCT01003899 · Phase 2 · registry result, not featured evidence 0%Arm I (Afatinib Dimaleate, Pembrol NCT02364609 · Phase 1 · registry result, not featured evidence · combination 0%Arm II (Pembrolizumab, Afatinib Di NCT02364609 · Phase 1 · registry result, not featured evidence · combination —Afa40+Ctx250 NCT01090011 · Phase 1 · registry result, not featured evidence · combination —Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination —Afa40 Mono NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy —Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 0% NCT01074177 · Phase na · registry result, not featured evidence | n/a: no completion milestonei NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 16 more resultsn/a: no completion milestone NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 — NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 79.2% NCT04511533 · Phase 4 · registry result, not featured evidence n/a: no completion milestone NCT02382796 · Phase 2 · registry result, not featured evidence n/a: no completion milestone45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence n/a: no completion milestone45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence 50%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 36.4%45 mg + 100 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 0%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 43.3%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 48%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneDacomitinib: Cohort A NCT00818441 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneDacomitinib: Cohort B NCT00818441 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT00769067 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePF-00299804 (Adenocarcinoma Histol NCT00548093 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePF-00299804 (Non-adenocarcinoma Hi NCT00548093 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 12.2%40 mgh NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 32 more results—50 mg/Day NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 13.1%50 mg/Day NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —40 mg NCT00525148 · Phase 2 —50 mg NCT00525148 · Phase 2 9.9%40mg NCT01121393 · Phase 3 17.1% NCT01523587 · Phase 3 20%40 mg NCT02208843 · Phase 4 · registry result, not featured evidence 12.9% NCT01853826 · Phase 3 · registry result, not featured evidence 3.7% NCT01953913 · Phase 3 · registry result, not featured evidence —40 mg NCT02044380 · Phase 3 · registry result, not featured evidence 19.3%Afatinib Monotherapy (Part A) NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy —Afatinib Plus Paclitaxel (Part B) NCT01085136 · Phase 3 · registry result, not featured evidence · combination 22.2%40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination 22.7%40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination 41.7%40 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination 33.3%30 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination —40 mg NCT02597946 · Phase 2 · registry result, not featured evidence — NCT02369484 · Phase 2 · registry result, not featured evidence 0%40 mg NCT00711594 · Phase 2 · registry result, not featured evidence 0%50 mg NCT00711594 · Phase 2 · registry result, not featured evidence 25.8%50 mg NCT00711594 · Phase 2 · registry result, not featured evidence 33.3%20 mg NCT00711594 · Phase 2 · registry result, not featured evidence 5%50 mg NCT00796549 · Phase 2 · registry result, not featured evidence —50 mg NCT00730925 · Phase 2 · registry result, not featured evidence 17%40 mg NCT01003899 · Phase 2 · registry result, not featured evidence —Arm I (Afatinib Dimaleate, Pembrol NCT02364609 · Phase 1 · registry result, not featured evidence · combination —Arm II (Pembrolizumab, Afatinib Di NCT02364609 · Phase 1 · registry result, not featured evidence · combination —Afa40+Ctx250 NCT01090011 · Phase 1 · registry result, not featured evidence · combination —Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination —Afa40 Mono NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy —Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination — NCT01074177 · Phase na · registry result, not featured evidence | —i NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 16 more results— NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 — NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 — NCT04511533 · Phase 4 · registry result, not featured evidence — NCT02382796 · Phase 2 · registry result, not featured evidence 18.8%45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence 4%45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence —45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination —45 mg + 100 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination —45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination —45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination —45 mg NCT01465802 · Phase 2 · registry result, not featured evidence 0%Dacomitinib: Cohort A NCT00818441 · Phase 2 · registry result, not featured evidence 3.3%Dacomitinib: Cohort B NCT00818441 · Phase 2 · registry result, not featured evidence — NCT00769067 · Phase 2 · registry result, not featured evidence —PF-00299804 (Adenocarcinoma Histol NCT00548093 · Phase 2 · registry result, not featured evidence —PF-00299804 (Non-adenocarcinoma Hi NCT00548093 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 31.4%40 mgh NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 32 more results34.9%50 mg/Day NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —50 mg/Day NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 30%40 mg NCT00525148 · Phase 2 44.4%50 mg NCT00525148 · Phase 2 16.7%40mg NCT01121393 · Phase 3 44.4% NCT01523587 · Phase 3 35%40 mg NCT02208843 · Phase 4 · registry result, not featured evidence 43.8% NCT01853826 · Phase 3 · registry result, not featured evidence 30.3% NCT01953913 · Phase 3 · registry result, not featured evidence 21.4%40 mg NCT02044380 · Phase 3 · registry result, not featured evidence 40.8%Afatinib Monotherapy (Part A) NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy 40.3%Afatinib Plus Paclitaxel (Part B) NCT01085136 · Phase 3 · registry result, not featured evidence · combination 55.6%40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination 22.7%40 mg NCT01814553 · Phase 3 · registry result, not featured evidence · combination 33.3%40 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination 75%30 mg + 200 mg NCT03157089 · Phase 2 · registry result, not featured evidence · combination 33.3%40 mg NCT02597946 · Phase 2 · registry result, not featured evidence 38.5% NCT02369484 · Phase 2 · registry result, not featured evidence 0%40 mg NCT00711594 · Phase 2 · registry result, not featured evidence 33.3%50 mg NCT00711594 · Phase 2 · registry result, not featured evidence 25.8%50 mg NCT00711594 · Phase 2 · registry result, not featured evidence 33.3%20 mg NCT00711594 · Phase 2 · registry result, not featured evidence 50.7%50 mg NCT00796549 · Phase 2 · registry result, not featured evidence 46.3%50 mg NCT00730925 · Phase 2 · registry result, not featured evidence 40.5%40 mg NCT01003899 · Phase 2 · registry result, not featured evidence 0%Arm I (Afatinib Dimaleate, Pembrol NCT02364609 · Phase 1 · registry result, not featured evidence · combination 40%Arm II (Pembrolizumab, Afatinib Di NCT02364609 · Phase 1 · registry result, not featured evidence · combination 75%Afa40+Ctx250 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 50%Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 32.4%Afa40 Mono NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy 41.7%Afa40+Ctx500 NCT01090011 · Phase 1 · registry result, not featured evidence · combination 12.5% NCT01074177 · Phase na · registry result, not featured evidence | 30.4%i NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 16 more results40.8% NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 40% NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 15.8% NCT04511533 · Phase 4 · registry result, not featured evidence 28.6% NCT02382796 · Phase 2 · registry result, not featured evidence 43.8%45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence 36.4%45/60 mg NCT01858389 · Phase 2 · registry result, not featured evidence 37.9%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 40.9%45 mg + 100 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 42.9%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 32.8%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence · combination 24%45 mg NCT01465802 · Phase 2 · registry result, not featured evidence 32.6%Dacomitinib: Cohort A NCT00818441 · Phase 2 · registry result, not featured evidence 30%Dacomitinib: Cohort B NCT00818441 · Phase 2 · registry result, not featured evidence 36.6% NCT00769067 · Phase 2 · registry result, not featured evidence 18%PF-00299804 (Adenocarcinoma Histol NCT00548093 · Phase 2 · registry result, not featured evidence 37.5%PF-00299804 (Non-adenocarcinoma Hi NCT00548093 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 40 mgh diarrhoea 94.3% rash 63.3% paronychia 57.6% NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 31 more results50 mg/Day diarrhoea 85.6% (placebo 9.2%) rash 63.6% (placebo 11.8%) paronychia 33.6% (placebo 0.5%) NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 40 mg diarrhoea 73.3% rash 30% paronychia 23.3% NCT02208843 · Phase 4 · registry result, not featured evidence diarrhoea 49.7% rash 29.9% paronychia 17.7% NCT01853826 · Phase 3 · registry result, not featured evidence diarrhoea 89.3% rash 70.8% paronychia 50.1% NCT01953913 · Phase 3 · registry result, not featured evidence 40 mg diarrhoea 92.9% decreased appetite 42.9% nausea 42.9% NCT02044380 · Phase 3 · registry result, not featured evidence diarrhoea 83.5% rash 54.5% paronychia 29.6% NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy diarrhoea 53.7% alopecia 35.1% asthenia 35.1% NCT01085136 · Phase 3 · registry result, not featured evidence · combination 40 mg diarrhoea 88.9% nausea 66.7% dry skin 44.4% NCT01814553 · Phase 3 · registry result, not featured evidence · combination 40 mg diarrhoea 81.8% constipation 50% dermatitis acneiform 36.4% NCT01814553 · Phase 3 · registry result, not featured evidence · combination 40 mg + 200 mg diarrhoea 91.7% decreased appetite 50% rash 41.7% NCT03157089 · Phase 2 · registry result, not featured evidence · combination 30 mg + 200 mg diarrhoea 58.3% dermatitis acneiform 41.7% fatigue 33.3% NCT03157089 · Phase 2 · registry result, not featured evidence · combination 40 mg diarrhoea 66.7% rash 33.3% anaemia 22.2% NCT02597946 · Phase 2 · registry result, not featured evidence diarrhea 84.6% paronyclia 38.5% erythema multiforme 30.8% NCT02369484 · Phase 2 · registry result, not featured evidence 40 mg nausea 100% rash 100% stomatitis 100% NCT00711594 · Phase 2 · registry result, not featured evidence 50 mg diarrhoea 100% dry skin 83.3% acne 50% NCT00711594 · Phase 2 · registry result, not featured evidence 50 mg diarrhoea 93.5% rash 85.5% paronychia 67.7% NCT00711594 · Phase 2 · registry result, not featured evidence 20 mg dry skin 100% malaise 100% rash 100% NCT00711594 · Phase 2 · registry result, not featured evidence 50 mg diarrhoea 76.8% rash 73.9% mucosal inflammation 29% NCT00796549 · Phase 2 · registry result, not featured evidence 50 mg diarrhoea 87.8% rash 68.3% decreased appetite 53.7% NCT00730925 · Phase 2 · registry result, not featured evidence 40 mg rash 76.2% diarrhoea 61.9% decreased appetite 42.9% NCT01003899 · Phase 2 · registry result, not featured evidence anemia 83.3% diarrhea 83.3% anorexia 66.7% NCT02364609 · Phase 1 · registry result, not featured evidence · combination nausea 100% diarrhea 80% anemia 60% NCT02364609 · Phase 1 · registry result, not featured evidence · combination Afa40+Ctx250 fatigue 75% nausea 75% chest pain 50% NCT01090011 · Phase 1 · registry result, not featured evidence · combination Afa40+Ctx500 rash 84.1% diarrhoea 73% skin fissures 61.9% NCT01090011 · Phase 1 · registry result, not featured evidence · combination Afa40 Mono diarrhoea 73% fatigue 43.2% rash 37.8% NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy Afa40+Ctx500 rash 47.2% skin fissures 44.4% fatigue 38.9% NCT01090011 · Phase 1 · registry result, not featured evidence · combination head/headache 87.5% dysphagia 83.3% infection gr0-2 neut, oral cavity 54.2% NCT01074177 · Phase na · registry result, not featured evidence | i diarrhoea 87.7% paronychia 61.7% dermatitis acneiform 49.3% NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 16 more resultsdiarrhoea 73.9% rash 50% decreased appetite 31.7% NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 diarrhea 79.7% (placebo 19.7%) rash acneiform 59.3% (placebo 10%) dyspnea 57.9% (placebo 55.2%) NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 diarrhoea 51.5% rash 42.6% weight decreased 34.7% NCT04511533 · Phase 4 · registry result, not featured evidence contusion 28.6% diarrhoea 28.6% dry skin 28.6% NCT02382796 · Phase 2 · registry result, not featured evidence 45/60 mg diarrhoea 87.5% rash 50% dry skin 43.8% NCT01858389 · Phase 2 · registry result, not featured evidence 45/60 mg diarrhoea 72.7% rash 54.5% nausea 40.9% NCT01858389 · Phase 2 · registry result, not featured evidence 45 mg diarrhoea 81.8% nausea 42.4% rash 42.4% NCT01465802 · Phase 2 · registry result, not featured evidence · combination 45 mg + 100 mg diarrhoea 78.8% nausea 47% rash 43.9% NCT01465802 · Phase 2 · registry result, not featured evidence · combination 45 mg diarrhoea 100% rash 71.4% chills 57.1% NCT01465802 · Phase 2 · registry result, not featured evidence · combination 45 mg diarrhoea 80.6% decreased appetite 37.3% rash 37.3% NCT01465802 · Phase 2 · registry result, not featured evidence · combination 45 mg diarrhoea 92% dermatitis acneiform 72% pruritus 68% NCT01465802 · Phase 2 · registry result, not featured evidence diarrhoea 95.5% dermatitis acneiform 76.4% dry skin 43.8% NCT00818441 · Phase 2 · registry result, not featured evidence diarrhoea 93.3% dermatitis acneiform 73.3% fatigue 56.7% NCT00818441 · Phase 2 · registry result, not featured evidence diarrhoea 72% dermatitis acneiform 64.5% decreased appetite 29% NCT00769067 · Phase 2 · registry result, not featured evidence diarrhoea 88% dermatitis acneiform 66% fatigue 62% NCT00548093 · Phase 2 · registry result, not featured evidence diarrhoea 81.3% dermatitis acneiform 75% dry skin 43.8% NCT00548093 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 4.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eTrial phases differ: Phase 4 versus Phase 2.
- fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- gTrial phases differ: Phase 2 versus Phase na.
- hPopulation comparability has not been reviewed for 30 of these studies.
- iPopulation comparability has not been reviewed for 14 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Afatinib
show 1 more result
show 6 more results
show 13 more results
+ 27 further endpoints in the CSV export.
Dacomitinib PF-00299804
show 1 more result
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 14 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afatinib's landscape · Dacomitinib PF-00299804's landscape